NCT00934050已完成2 期
A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 103
- 试验地点
- 38
- 主要终点
- Treatment Emergent Adverse Events (TEAEs)
研究概览
简要总结
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.
排除标准
- •Subject has no new medical contraindications to continued participation in the study.
研究组 & 干预措施
ELND005
Experimental
干预措施: ELND005 (scyllo-inositol) (Drug)
结局指标
主要结局
Treatment Emergent Adverse Events (TEAEs)
时间窗: 12 months
Safety and Tolerability was assessed by the incidence of Treatment Emergent Adverse Events (TEAEs)
次要结局
未报告次要终点
研究者
研究点 (38)
Loading locations...
相似试验
终止
2 期
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseAlzheimer's DiseaseNCT01766336OPKO Health, Inc.296
终止
1 期
A Study of ELND002 in Patients With Relapsing Forms of Multiple SclerosisMultiple SclerosisNCT01318421Elan Pharmaceuticals12
已完成
3 期
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCarcinoid SyndromeNCT02026063Lexicon Pharmaceuticals124
已完成
3 期
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT02079246H. Lundbeck A/S1,463
已完成
2 期
Long-term Safety in Atrial Fibrillation PatientsPersistent or Permanent Nonvalvular Atrial FibrillationNCT00645853AstraZeneca523